Continuous Blood Glucose Monitoring Market Report 2025

This Continuous Blood Glucose Monitoring market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The continuous blood glucose monitoring market size has grown strongly in recent years. It will grow from $13.57 billion in 2024 to $14.87 billion in 2025 at a compound annual growth rate (CAGR) of 9.6%. The growth in the historic period can be attributed to increase in diabetes prevalence, regulatory compliance, demand for remote monitoring, emerging markets, rise in healthcare spending.

The continuous blood glucose monitoring market size is expected to see rapid growth in the next few years. It will grow to $23.15 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to growing aging population, rising home healthcare, telehealth expansion, rise in healthcare expenditure, rise in disposable income. Major trends in the forecast period include wearable integration, artificial intelligence and machine learning, advanced sensors and accuracy, partnerships and collaboration.

The rising prevalence of diabetes is expected to drive the growth of the continuous blood glucose monitoring market in the future. Diabetes is a health condition characterized by fluctuating blood glucose levels in the body. Blood glucose monitoring devices help identify trends and patterns that provide a clearer overall picture of a diabetic individual's condition. For example, the International Diabetes Federation (IDF) recently reported that approximately 537 million adults aged 20 to 79 are currently living with diabetes worldwide. This figure represents a significant increase from earlier estimates and underscores a troubling trend in diabetes prevalence. The IDF anticipates that this number will reach 643 million by 2030 and further rise to 783 million by 2045. Therefore, the increasing prevalence of diabetes is propelling the growth of the continuous blood glucose monitoring market in the coming years.

The proliferation of hospitals is poised to contribute to the expansion of the continuous blood glucose monitoring market. Hospitals, dedicated to providing medical or surgical treatment, find continuous blood glucose monitoring crucial for precise and ongoing monitoring of blood glucose levels, particularly for patients with diabetes or those at risk of glucose-related complications. According to Discovery Therapy in September 2023, the US had around 6,090 hospitals in 2021, while globally, there were approximately 165,000 hospitals. Additionally, the American Hospital Association reported in May 2023 that there were 6,129 hospitals in America in 2022. The increased number of hospitals globally is expected to drive the growth of the continuous blood glucose monitoring market.

Technological advancements have become a significant trend gaining traction in the continuous blood glucose monitoring market. Major companies in this sector are concentrating on developing cutting-edge technological solutions to strengthen their market position. For example, in 2022, Philips broadened its range of home care solutions for patients with chronic obstructive pulmonary disease (COPD) by launching the BiPAP A40 EFL, a non-invasive ventilator designed to improve patient comfort and decrease hospital readmissions. This ventilator utilizes Philips' proprietary ExpiraFlow technology, which enables healthcare professionals to automatically detect expiratory flow limitation (EFL) in COPD patients and deliver personalized therapy.

Major companies in the diabetes care devices market are innovating new products, such as the Medtronic Extended Infusion Set, to enhance their profitability. The Medtronic Extended Infusion Set is a tubing system designed to deliver insulin from the pump to the body, with a wear duration of up to 7 days. For instance, in 2023, Medtronic Plc expanded the availability of its Extended Infusion Set, which was initially launched in select European countries, to include additional markets throughout Europe and the Asia-Pacific region. This innovative device continues to simplify the insulin delivery process for diabetes patients, featuring a user-friendly all-in-one serter that makes set changes more efficient. The Extended Infusion Set allows for extended wear of up to 7 days, thanks to its advanced technology and materials, significantly exceeding the standard wear duration of typical infusion sets.

In a strategic move in May 2023, Medtronic PLC., an Ireland-based medical device company, acquired EOFlow for an undisclosed amount. This acquisition is geared towards strengthening Medtronic's diabetes product portfolio and expanding its capacity to offer comprehensive support to a larger global community managing diabetes, all within a unified Medtronic ecosystem. EOFlow Co. Ltd., based in South Korea, is recognized for manufacturing the insulin patch pump EOPatch. This strategic acquisition aligns with Medtronic's commitment to continuous growth and innovation in the diabetes care devices market.

Continuous Blood Glucose Monitoring (CGM) involves using a sensor under the skin to constantly track glucose levels. It provides real-time data and alerts for high or low glucose, assisting people with diabetes in managing their blood sugar levels more effectively.

The main components in continuous blood glucose monitoring devices include insulin pumps, sensors, transmitters, and receivers. Insulin pumps are compact, computerized devices that are programmed to administer pre-determined doses of insulin at specific intervals. These devices are particularly utilized by individuals with type 1 diabetes, type 2 diabetes, gestational diabetes, and critical care patients. The end-users for continuous blood glucose monitoring devices include hospitals, homecare diagnostics, and various other settings.

The continuous blood glucose monitoring market research report is one of a series of new reports that provides continuous blood glucose monitoring market statistics, including continuous blood glucose monitoring industry global market size, regional shares, competitors with a continuous blood glucose monitoring market share, detailed continuous blood glucose monitoring market segments, market trends and opportunities, and any further data you may need to thrive in the continuous blood glucose monitoring industry. This continuous blood glucose monitoring market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the continous blood glucose monitoring market include F. Hoffmann-La Roche Ltd., Lifescan Inc., Medtronic plc., Abbott Laboratories, GlySens Inc., Arkray, Senseonics Holdings Inc., Glysure Limited, Nemaura Medical Inc., Tandem Diabetes Care Inc., Goldsite Diagnostics Inc., AgaMatrix Inc., B. Braun Melsungen AG, Ypsomed Holding AG, Terumo Corporation, Orsense Ltd., Dexcom Inc., A. Menarini Diagnostics, Echo Therapeutics Inc., Johnson & Johnson Services Inc., Ascensia Diabetes Care Holdings AG, Insulet Corporation, Medtrum Technologies Inc., Texas Instruments Inc., Beta Bionics Inc., Bigfoot Biomedical Inc., One Drop Inc., DarioHealth Corp., MedAngel BV, GluSense Ltd., PKvitality, Nemotecnia S.A.

North America was the largest region in the continuous blood glucose monitoring market in 2023. The regions covered in the continuous blood glucose monitoring market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the continuous blood glucose monitoring market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The continuous blood glucose monitoring market consists of sales of real-time continuous glucose monitoring, and intermittently scanned continuous glucose monitoring. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.